LSE Capital Limited (LSECL) has approved its participation in a joint venture (JV) arrangement with LABLINK Enterprises to pursue pre-qualification and bidding for a project in Sindh.
According to a notice submitted to the Pakistan Stock Exchange (PSX) on November 5, 2026, the company’s Board of Directors approved the proposed joint venture through a resolution passed by circulation.
LABLINK Enterprises is a registered sole proprietorship engaged in the import, distribution and supply of medical, healthcare and surgical products and equipment. The company supplies products from multinational principals, including NIPRO and Baxter.
Under the proposed arrangement, LSE Capital and LABLINK Enterprises will collaborate to participate in the pre-qualification and bidding process for a project in the province of Sindh.
The development marks a move by LSE Capital to explore business opportunities through collaboration with an established healthcare and medical equipment supplier.
The company formally communicated the board’s decision to the Pakistan Stock Exchange and requested dissemination of the information to its Trading Rights Entitlement Certificate (TREC) holders.
The disclosure was also copied to the Securities and Exchange Commission of Pakistan (SECP) in accordance with the relevant regulatory communication process.
Further details regarding the project’s scope, financial arrangements, bidding outcome and potential revenue impact were not disclosed in the notification.
